UMRX
Unum Therapeutics, Inc.
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
Unum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient’s immune system to cure cancer. The firm’s technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.
Market Cap: 99.8 Million
Primary Exchange: NASDAQ
Website: http://www.unumrx.com
Shares Outstanding: 42.5 Million
Float: 17 Million
Dividend: (%)
Beta: 1.1290933163315184
Sector: Health Technology
Industry: Biotechnology
Ethical Flags
Longest drawdown: 1069 trading days
From: 2018-07-31 To: 2020-10-05
Lowest Point:
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|